Why Bromantane Research Is Hard to Access

A PubMed query for bromantane, bromantan or ladasten returns 74 records. Fifty-six of them name the compound in the title; forty-five of those fifty-six are in Russian, and forty-five carry no digital object identifier in the PubMed record at all. Six carry no abstract in any language.

Those counts are the honest starting point for why bromantane research is hard to access, and they matter more than any summary of what the compound is said to do. A bibliographic record without an abstract is a citation, not a finding.

What an Actoprotector Was Meant to Be

The category is a translation problem before the individual papers are. A 2012 review in Biomolecules and Therapeutics, one of the few English language treatments of the class, defines actoprotectors as preparations that enhance stability against physical loads without increasing oxygen consumption or heat production, and calls them synthetic adaptogens. It names bemitil and bromantane as the main representatives.

A 2021 systematic review in Nutrients uses the same framing from the adaptogen side, listing bromantane, levamisole, aphobazole and bemethyl as synthetic compounds in a category otherwise dominated by plant extracts. Neither review is a primary source for any measurement. Both establish one thing: the class name is real, has a definition, and maps onto no Western category.

Why Bromantane Research Is Hard to Access Outside Russian

The obstacle is not only language. It is the structure of the record.

Forty of the forty-five Russian language entries do carry an English abstract, which sounds encouraging until the English language entries are read. Several, published in Bulletin of Experimental Biology and Medicine, have abstracts of two or three sentences that state what was studied and stop. A 2010 proteomic analysis reports that thirteen proteins with various levels of expression were identified, and names none of them. A 2009 study of the transcription factor CREB states that transcription factors with affected DNA binding activity were identified, without listing which. A 2012 paper on neurotrophin and kinase gene expression describes the measurements and gives no result at all.

These abstracts run between roughly 230 and 330 characters. They are methods statements. Whatever those experiments found is in the full text and not in the index.

One more feature is worth stating because it is checkable. The same multicentre clinical report appears twice under two PubMed identifiers, 21322821 and 20559263, with the same title, journal, volume and page range, distinguished only by whether the issue is recorded as a part or a supplement. Counting papers here by counting records will overcount.

One caveat. Those figures come from a text query plus a hand applied title filter, so the set includes records where the compound is only a comparator; they describe the accessibility of the record, not the size of the field.

Where the Indexed Record Actually Starts

Here the measurement contradicts the expectation the title sets up. The earliest publication date among the fifty-six title matching records is 1993 and the latest 2014, with thirteen entries from the 1990s, twenty-eight from the 2000s and fifteen from the 2010s.

Whatever work preceded 1993 is therefore not represented in the index searched. It may exist in institute reports, dissertations and journals never indexed abroad. Nothing here reconstructs it, because rebuilding a result from secondary description is how fabricated numbers enter a literature. The defensible statement is the negative one: that work is not retrievable through the sources used here.

Identifier	Value from PubChem
Compound identifier	4660557
Registry number	87913-26-6
Molecular formula	C16H20BrN
Molecular weight	306.24 g/mol
Systematic name	N-(4-bromophenyl)adamantan-2-amine

That systematic name matches the form written in the primary literature as N-(2-adamantyl)-N-(para-bromophenyl)-amine. Bromantane and ladasten are one molecule under a laboratory name and a trade name, which is why a search on one term returns a partial set. Identity of this kind is established analytically rather than assumed from a label, which is the role of a characterised bromantane analytical reference standard.

What the Tyrosine Hydroxylase Experiments Reported

The mechanistic thread that survives translation concerns dopamine biosynthesis.

A 2004 paper in Eksperimentalnaya i Klinicheskaya Farmakologiya, Russian with an English abstract, examined transcription of the tyrosine hydroxylase and DOPA decarboxylase genes alongside dopamine and L-DOPA content in rat striatum and hypothalamus, as a function of how long the compound had been acting. In the first hours the dopaminergic effect was attributed to increased dopamine release. Later accumulation of L-DOPA and dopamine correlated with transcriptional activity of both genes, read by the authors as activation of de novo enzyme synthesis, with a pattern differing between the two regions.

That is a gene expression claim, not a receptor claim. Nothing in these abstracts describes the compound as binding a transporter or receptor; the proposed action is on how much enzyme the cell makes.

A companion paper in Doklady Biochemistry and Biophysics in 2005 carries the title “The effect of ladasten on gene expression in the rat brain” and, in PubMed, no abstract at all. It is listed here as a bibliographic record. No sentence in this article derives from it.

The One Paper With a Complete Mechanistic Abstract

A 2007 study in Neuropharmacology is the exception, and the only source cited here that supports detailed statements.

Working in rats, it measured catecholamine biosynthesis in the ventral tegmental area, nucleus accumbens, hypothalamus, striatum and hippocampus, and found that the compound differentially regulates tyrosine hydroxylase messenger RNA and protein as well as dopamine and L-DOPA content. The word doing the work is differentially: direction was not uniform across regions.

The second half of the paper moved to hippocampal slices. Bath application at 10 micromolar transformed short term potentiation of synaptic transmission into a long lasting form. The same transformation occurred when the compound was applied 40 minutes after a single tetanisation at 100 hertz for 200 milliseconds, which places the effect after induction rather than during it. The reinforcement was blocked by the protein synthesis inhibitor anisomycin and attenuated by the D1 and D5 receptor antagonist SCH23390.

Two controls, two mechanisms implicated: protein synthesis and dopamine receptor signalling. That is the dual profile in its defensible form, and it is a statement about rat hippocampal slices.

What the Toxicology Papers Contain

The safety literature is in English, and it is not reassuring.

A neurotoxicological profile published in Bulletin of Experimental Biology and Medicine in 2002 applied the Irwin multi test observation protocol in rats and reported a biphasic pattern: behavioural and motor activity rose at lower amounts and were suppressed at higher ones. Mydriasis occurred at every amount examined. At the top of the range the authors recorded blepharoptosis, altered respiration, regurgitation, diarrhoea and polyuria, and rectal temperature fell across nearly the whole range.

A 2001 study in Neurotoxicology and Teratology, which describes the compound as then widely used in Russia in sport and as an immunostimulant, looked for reproductive and developmental effects in rats. Litter size fell at the lowest and highest amounts tested and rose at the intermediate one, a pattern that is not monotonic and that the authors did not resolve. Reflex development in pups differed from controls on two of the measured parameters, and passive avoidance retention latencies increased in all treated groups relative to their own training day.

Why the Clinical Record Cannot Be Checked From Outside

A multicentre report from 28 Russian centres, covering 728 patients with asthenic disorders, sits in the index in Russian with an English abstract, as does a phase II pilot trial. Both report favourable conclusions. Neither carries a DOI, neither gives a protocol or registration number in its abstract, and the full texts are not accessible through the channels used here.

The results can therefore be cited but not examined. A trial abstract does not show randomisation, blinding, handling of dropouts or pre specification of endpoints, and there is no linked record to check any of it against. Seen from outside Russian language archives, this clinical evidence base is reported rather than verified.

Frequently asked questions

What is an actoprotector in Soviet pharmacology?

A class defined by a 2012 English language review as preparations that increase stability against physical loads without raising oxygen consumption or heat production, described there as synthetic adaptogens. Bemitil and bromantane are named as the main representatives. The category has no direct Western equivalent.

Is bromantane the same compound as ladasten?

Yes. Both names refer to N-(4-bromophenyl)adamantan-2-amine, written in the primary literature as N-(2-adamantyl)-N-(para-bromophenyl)-amine. PubChem lists it under compound identifier 4660557, formula C16H20BrN. Searching one name alone returns an incomplete set, which is why the literature looks smaller than it is.

Why is most bromantane research published in Russian?

Because the work was done in Russian language institutions and published in their journals. Of 56 PubMed records naming the compound in the title, 45 are Russian entries. Forty carry an English abstract, so the barrier is less the abstract language than the missing full texts and identifiers.

Does bromantane increase tyrosine hydroxylase expression?

That is what the cited experiments report. A 2004 Russian paper found L-DOPA and dopamine accumulation correlating with transcriptional activity of the tyrosine hydroxylase and DOPA decarboxylase genes. A 2007 study in Neuropharmacology reported differential regulation of tyrosine hydroxylase messenger RNA and protein across five rat brain regions.

What did the hippocampal slice experiment show?

Application at 10 micromolar converted short term potentiation into a long lasting form in rat hippocampal slices, including when applied 40 minutes after tetanisation. Anisomycin blocked the effect and the D1 and D5 antagonist SCH23390 attenuated it, implicating protein synthesis and dopamine signalling.

How many bromantane papers carry an English abstract?

In the set measured for this article, 50 of 56 title matching PubMed records carry an abstract and 6 carry none. Several English abstracts are two or three sentences describing methods without reporting results, so their presence guarantees less than the count suggests.

What did the reproductive toxicity study report?

A 2001 study in Neurotoxicology and Teratology found litter size decreased at the lowest and highest amounts tested and increased at the intermediate one, a non-monotonic pattern left unexplained. Two reflex development parameters differed from controls, and passive avoidance retention latencies rose in all treated groups.

References

Research use only. Nonsensia Lab supplies analytical reference standards for laboratory and research applications. This article is published for scientific and educational purposes. It is not medical advice, it does not describe any use in humans, and nothing in it should be read as a recommendation to administer any substance to a person or animal.

Filed under: Nootropics Research

This article is part of our guide to The Evidence Base for Cognition Research Compounds: A Critical Guide.

The compound discussed in this article is available as an analytical reference standard: Bromantane ≥99.75% HPLC – Analytical Reference Standard | CAS 87913-26-6.

Bromantane’s Dual Profile: Actoprotector Research from the Soviet Era